Cardiovascular Journal of Africa: Vol 32 No 5 (SEPTEMBER/OCTOBER 2021)

DOXAZOSIN 4 mg consistent flow 1 Slower onset for COST SAVING vs THE ORIGINATOR 4 % 53 MORE THAN CARZIN XL. Each tablet contains 4 mg doxazosin. S3 A41/7.1/0557. NAM NS2 10/34/0376. For full prescribing information, refer to the professional information approved by SAHPRA, 12 June 2015. 1) Pompeo ACL, et al. A randomised, double blind study comparing the efficacy and tolerability of controlled release Doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia. Int J. Clin Pract Oct 2006;60(10):1172-1177. 2) Kirby RS, et al. A Combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. British Journal of Urology International 2001 Feb;87(3):192-200. 3) Approved professional information. 4) Database of Medicine Prices (1 July 2021). Department of Health website. http://www.mpr.gov.za . CXLD779/10/2021. A slower onset of action vs IR formulations to allow fewer titration steps and to minimize side-eects. 2 E ective treatment for urinary outflow obstruction and BPH symptoms. 3 Safe BPH treatment for normotensive and hypertensive patients. 3 Carzin XL , the extended release doxazosin oers: For further product information contact PHARMA DYNAMICS P O Box 30958 Tokai Cape Town 7966 Fax +27 21 701 5898 Email info@pharmadynamics.co.za CUSTOMER CARE LINE 0860 PHARMA (742 762) / +27 21 707 7000 www.pharmadynamics.co.za